{"id":"NCT00831129","sponsor":"University of Chicago","briefTitle":"A Study for Pre-diabetic Patients With Cholesterol Lowering Drugs","officialTitle":"Effects of Simvastatin and Rosiglitazone Combination in Patients With the Metabolic Syndrome.","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2006-09","primaryCompletion":"2011-03","completion":"2011-04","firstPosted":"2009-01-28","resultsPosted":"2013-09-12","lastUpdate":"2017-02-10"},"enrollment":53,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":null},"conditions":["Pre-diabetes"],"interventions":[{"type":"DRUG","name":"Rosiglitazone","otherNames":["Avandia"]},{"type":"DRUG","name":"Placebo Rosiglitazone","otherNames":["Placebo"]},{"type":"DRUG","name":"Simvastatin","otherNames":["Zocor"]}],"arms":[{"label":"Simvastatin + Placebo Rosiglitazone","type":"ACTIVE_COMPARATOR"},{"label":"Simvastatin + rosiglitazone","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this research study is to examine if a combination of a cholesterol lowering-drug, simvastatin, with a sugar-lowering drug called rosiglitazone is more effective in improving vascular inflammation (irritation of the vessels that transport your blood) and other cardiovascular risk factors than the taking of simvastatin alone.","primaryOutcome":{"measure":"Change in High-sensitivity C-reactive Protein","timeFrame":"Baseline and 6 months","effectByArm":[{"arm":"Placebo","deltaMin":0.72,"sd":2.49},{"arm":"Rosiglitazone","deltaMin":-0.61,"sd":1.36}],"pValues":[]},"eligibility":{"minAge":"21 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":7,"exclusionCount":9},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":20},"commonTop":["Nonspecific muscle aches in lower extremities","Joint aches","Upper respiratory symptoms","Nausea Vomiting","Headaches"]}}